• National High-tech Enterprise Awarded for 15 consecutive years • Top 20 Chinese Pharmaceutical R&D Companies Awarded for three consecutive years • 30+ Invention Patents Applied • 70+ clinical & Production & New Drug Certifications Approved • 10+ International Registration (EU, FDA, etc. ) Submitted • 100+ Technology Transfer Finished • 20+ Series products commercialized
• Obtain the first CEP certificate • Obtain CNAS certificate • Submit MAH registration application for the first time and obtain B certificate • Two API varieties have been approved by CDE and transferred to A
• Jinghai Industrial Park R&D Center Operated • Strategic Partnership with Zezheng Pharmaceutical Established
• Subsidiary HMYA Established, International Business Operated Independently • EU & FDA Application Submitted • Top 20 Chinese Pharmaceutical R&D Companies Awarded (Reelected) • CSAIII Pilot • T100 New Technology & New Product Innovation Action Outstanding Enterprise Awarded
• Strategic Partnership with PPC Group Established • Top 20 Chinese Pharmaceutical R&D Companies Awarded (Reelected)
• Strategic Partnership with Porton Pharmaceutical Established • Top 20 Chinese Pharmaceutical R&D Companies Awarded